<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="229681">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00090285</url>
  </required_header>
  <id_info>
    <org_study_id>V501-020</org_study_id>
    <secondary_id>Formerly-0904HPVHMES</secondary_id>
    <secondary_id>2004_103</secondary_id>
    <nct_id>NCT00090285</nct_id>
  </id_info>
  <brief_title>An Investigational Study of Gardasil™ (qHPV, V501) Vaccine in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)</brief_title>
  <official_title>An Investigational Vaccine in Reducing the Incidence of Anogenital Warts in Young Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This study is to evaluate an investigational vaccine with the following objectives: to
      demonstrate that the vaccine is well tolerated in young men; to demonstrate that the vaccine
      reduces incidence of external genital lesions (Condylomata acuminata [anogenital warts],
      penile/perianal/perineal intraepithelial neoplasia [PIN], penile, perianal, perineal cancer)
      in young men; to demonstrate that the vaccine reduces the incidence of anal intraepithelial
      neoplasia (AIN) or anal cancer in men having sex with men (MSM); and to demonstrate that the
      vaccine reduces incidence of Human Papilloma Virus (HPV) infection in young men.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The base study (V501-020) encompassed Day 1 through Month 7, during which time participants
      received randomly assigned Gardasil™ (qHPV vaccine) or placebo at Day 1, Month 2, and Month
      6. Base study follow-up continued through Month 36.

      The base study was extended in protocol V501-020-10 Extension 1 (EXT1). Participants who
      received placebo and participants who received only 1 dose of qHPV vaccine in the base study
      were offered a complete 3-dose qHPV vaccine regimen (administered at EXT1 Day 1, Month 2 and
      Month 6). Participants who received only 2 doses of qHPV vaccine in the base study were
      offered a single additional dose of qHPV vaccine (administered at EXT1 Day 1). Participants
      were followed to EXT1 Month 7.

      A second extension study, V501-020-21 (EXT2), will estimate the long-term safety and
      effectiveness of qHPV vaccine during a period of 10 years following initial enrollment in
      the base study. Subjects who received at least one dose of qHPV vaccine in either the base
      study or EXT1 are eligible to enroll in EXT2.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Human Papillomavirus (HPV) Related External Genital Warts, Perineal Intraepithelial Neoplasia (PIN), Penile, Perianal or Perineal Cancer</measure>
    <time_frame>Base study: through Month 36</time_frame>
    <description>Subjects with HPV 6/11/16/18-related external genital warts, PIN, penile, perianal or perineal cancer per 100 person-years of follow-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Severe Injection Site Adverse Experiences (AEs)</measure>
    <time_frame>Base study: through Day 5 after any vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Vaccine-Related Serious Adverse Events (SAEs)</measure>
    <time_frame>Base study: through Month 36</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of HPV 6/11/16/18-related Persistent Infection</measure>
    <time_frame>Base study: through Month 36</time_frame>
    <description>Subjects with HPV 6/11/16/18-related persistent infection per 100 person-years of follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of HPV 6/11/16/18-related Deoxyribonucleic Acid (DNA) Detection</measure>
    <time_frame>Base study: through Month 36</time_frame>
    <description>Subjects with HPV 6/11/16/18-related DNA detection per 100 person-years of follow-up.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Substudy to Evaluate the Incidence of HPV 6/11/16/18-related Anal Intraepithelial Neoplasia (AIN) and Anal Cancer in Men Having Sex With Men (MSM)</measure>
    <time_frame>Base study: through Month 36</time_frame>
    <description>Participants with HPV 6/11/16/18-related AIN or anal cancer per 100 person-years of follow-up</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4065</enrollment>
  <condition>Condylomata Acuminata</condition>
  <arm_group>
    <arm_group_label>qHPV Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>(Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine</intervention_name>
    <description>Duration of Treatment: 6 months</description>
    <arm_group_label>qHPV Vaccine</arm_group_label>
    <other_name>qHPV</other_name>
    <other_name>V501</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: placebo (unspecified)</intervention_name>
    <description>Duration of Treatment: 6 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male between the ages of 16 years and 23 years and 364 days. For the MSM
             substudy, between the ages of 16 years and 26 years and 364 days.

          -  No clinical evidence of genital lesions suggesting sexually-transmitted disease, and
             no history of anogenital warts

          -  Additional criteria will be discussed with you by the physician

        Exclusion Criteria:

          -  Concurrently enrolled in a clinical study involving collection of genital specimens

          -  History of known prior vaccination with an HPV vaccine

          -  Received an inactivated vaccine within 14 days or a live virus vaccine within 21 days
             prior to enrollment

          -  History of a severe allergic reaction that required medical intervention

          -  Received any immune globulin or blood-derived products within 6 months prior to the
             first study injection

          -  History of splenectomy, immune disorders, or receiving immunosuppressives

          -  Immunocompromised or diagnosed with HIV infection

          -  Known thrombocytopenia or any coagulation disorder that would contraindicate
             intramuscular injections

          -  History of recent or ongoing alcohol or drug abuse
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Costa Rica</country>
    <country>Croatia</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Portugal</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 7, 2017</lastchanged_date>
  <firstreceived_date>August 25, 2004</firstreceived_date>
  <firstreceived_results_date>October 14, 2009</firstreceived_results_date>
  <firstreceived_results_disposition_date>October 7, 2009</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anogenital warts</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Overall study: first participant visit 03-Sept-2004; EXT1: first participant visit 16-Nov-2009, last participant visit 23-Sept-2011; EXT2: first participant visit 10-Aug-2010, last participant visit (estimated) 30-Dec-2017; study is currently ongoing</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>qHPV Vaccine in Base Study</title>
          <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time participants received qHPV vaccination at Day 1, Month 2 and Month 6.
Follow-up for the base study encompassed Month 7 through Month 36.</description>
        </group>
        <group group_id="P2">
          <title>Placebo in Base Study</title>
          <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time participants received placebo at Day 1, Month 2 and Month 6.
Follow-up for the base study encompassed Month 7 through Month 36.</description>
        </group>
        <group group_id="P3">
          <title>EXT1: Placebo in Base Study</title>
          <description>Participants in the placebo arm in the base study were offered 3 doses of open-label qHPV vaccine at EXT1 Day 1, Month 2 and Month 6. Participants were followed to EXT1 Month 7.</description>
        </group>
        <group group_id="P4">
          <title>EXT1: Incomplete qHPV Regimen in Base Study</title>
          <description>Participants who received placebo and participants who received only 1 dose of qHPV vaccine in the base study were offered a complete 3-dose qHPV vaccine regimen (administered at EXT1 Day 1, Month 2 and Month 6). Participants who received only 2 doses of qHPV vaccine in the base study were offered a single additional dose of qHPV vaccine (administered at EXT1 Day 1). Participants were followed to EXT1 Month 7.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Base Study Vaccination Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2032"/>
                <participants group_id="P2" count="2033"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="2025"/>
                <participants group_id="P2" count="2030"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1818"/>
                <participants group_id="P2" count="1814"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="214"/>
                <participants group_id="P2" count="219"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Randomized Not Vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="112"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="69"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Uncooperative</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Terminated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unspecified</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Incarcerated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>HIV positive</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Base Study Follow-up Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1822">4 subjects who did not receive 3 doses of vaccine in base study continued into the Follow-up Period</participants>
                <participants group_id="P2" count="1821">7 subjects who did not receive 3 doses of placebo in base study continued into the Follow-up Period</participants>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1487"/>
                <participants group_id="P2" count="1479"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="335"/>
                <participants group_id="P2" count="342"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="232"/>
                <participants group_id="P2" count="226"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unspecified</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Uncooperative</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Incarcerated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1098">Participation in EXT1 was voluntary; not all participants eligible for EXT1 enrolled.</participants>
                <participants group_id="P4" count="16">Participation in EXT1 was voluntary; not all participants eligible for EXT1 enrolled.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1041"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="57"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="35"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>qHPV Vaccine</title>
          <description>Participants who started the base study vaccination period</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants who started the base study vaccination period</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2032"/>
            <count group_id="B2" value="2033"/>
            <count group_id="B3" value="4065"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.6" spread="2.0"/>
                    <measurement group_id="B2" value="20.5" spread="2.0"/>
                    <measurement group_id="B3" value="20.5" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Although the upper age limit for this study was 26 years old, one subject age 27 was randomized into the study.</description>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20" lower_limit="16" upper_limit="26"/>
                    <measurement group_id="B2" value="20" lower_limit="15" upper_limit="27"/>
                    <measurement group_id="B3" value="20" lower_limit="15" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2032"/>
                    <measurement group_id="B2" value="2033"/>
                    <measurement group_id="B3" value="4065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="201"/>
                    <measurement group_id="B2" value="205"/>
                    <measurement group_id="B3" value="406"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="405"/>
                    <measurement group_id="B2" value="400"/>
                    <measurement group_id="B3" value="805"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="412"/>
                    <measurement group_id="B2" value="423"/>
                    <measurement group_id="B3" value="835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="719"/>
                    <measurement group_id="B2" value="712"/>
                    <measurement group_id="B3" value="1431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multi-Racial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="291"/>
                    <measurement group_id="B2" value="283"/>
                    <measurement group_id="B3" value="574"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indian (subcontinent)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polynesian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Human Papillomavirus (HPV) Related External Genital Warts, Perineal Intraepithelial Neoplasia (PIN), Penile, Perianal or Perineal Cancer</title>
        <description>Subjects with HPV 6/11/16/18-related external genital warts, PIN, penile, perianal or perineal cancer per 100 person-years of follow-up.</description>
        <time_frame>Base study: through Month 36</time_frame>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative to the relevant HPV type at Day 1 and polymerase chain reaction (PCR) negative to the relevant HPV type Day 1 through Month 7, and must provide follow-up data after Month 7.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time participants received qHPV vaccination at Day 1, Month 2 and Month 6.
Follow-up for the base study encompassed Month 7 through Month 36. Not all participants reached Month 36 prior to the cut-off for the pre-specified analysis.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time participants received placebo at Day 1, Month 2 and Month 6.
Follow-up for the base study encompassed Month 7 through Month 36. Not all participants reached Month 36 prior to the cut-off for the pre-specified analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Human Papillomavirus (HPV) Related External Genital Warts, Perineal Intraepithelial Neoplasia (PIN), Penile, Perianal or Perineal Cancer</title>
          <description>Subjects with HPV 6/11/16/18-related external genital warts, PIN, penile, perianal or perineal cancer per 100 person-years of follow-up.</description>
          <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative to the relevant HPV type at Day 1 and polymerase chain reaction (PCR) negative to the relevant HPV type Day 1 through Month 7, and must provide follow-up data after Month 7.</population>
          <units>Incidence per 100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1394"/>
                <count group_id="O2" value="1404"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Relative Risk Reduction</param_type>
            <param_value>90.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>70.1</ci_lower_limit>
            <ci_upper_limit>98.2</ci_upper_limit>
            <estimate_desc>Confidence Interval (CI) based on binomial tail probabilities and not from a dispersion parameter.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of HPV 6/11/16/18-related Persistent Infection</title>
        <description>Subjects with HPV 6/11/16/18-related persistent infection per 100 person-years of follow-up.</description>
        <time_frame>Base study: through Month 36</time_frame>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative to the relevant HPV type at Day 1 and PCR negative to the relevant HPV type Day 1 through Month 7, and must provide follow-up data after Month 7.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time participants received qHPV vaccination at Day 1, Month 2 and Month 6.
Follow-up for the base study encompassed Month 7 through Month 36. Not all participants reached Month 36 prior to the cut-off for the pre-specified analysis.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time participants received placebo at Day 1, Month 2 and Month 6.
Follow-up for the base study encompassed Month 7 through Month 36. Not all participants reached Month 36 prior to the cut-off for the pre-specified analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of HPV 6/11/16/18-related Persistent Infection</title>
          <description>Subjects with HPV 6/11/16/18-related persistent infection per 100 person-years of follow-up.</description>
          <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative to the relevant HPV type at Day 1 and PCR negative to the relevant HPV type Day 1 through Month 7, and must provide follow-up data after Month 7.</population>
          <units>Infection per 100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1390"/>
                <count group_id="O2" value="1402"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Relative Risk Reduction</param_type>
            <param_value>85.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>77.0</ci_lower_limit>
            <ci_upper_limit>91.3</ci_upper_limit>
            <estimate_desc>CI based on binomial tail probabilities and not from a dispersion parameter. Hochberg multiplicity adjustment applied to the CI.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of HPV 6/11/16/18-related Deoxyribonucleic Acid (DNA) Detection</title>
        <description>Subjects with HPV 6/11/16/18-related DNA detection per 100 person-years of follow-up.</description>
        <time_frame>Base study: through Month 36</time_frame>
        <population>Per-protocol population: subjects must
have no major protocol violations, must be seronegative to the relevant HPV type at Day 1 and PCR negative to
the relevant HPV type Day 1 through Month 7, and must provide follow-up data after Month 7.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time participants received qHPV vaccination at Day 1, Month 2 and Month 6.
Follow-up for the base study encompassed Month 7 through Month 36. Not all participants reached Month 36 prior to the cut-off for the pre-specified analysis.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time participants received placebo at Day 1, Month 2 and Month 6.
Follow-up for the base study encompassed Month 7 through Month 36. Not all participants reached Month 36 prior to the cut-off for the pre-specified analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of HPV 6/11/16/18-related Deoxyribonucleic Acid (DNA) Detection</title>
          <description>Subjects with HPV 6/11/16/18-related DNA detection per 100 person-years of follow-up.</description>
          <population>Per-protocol population: subjects must
have no major protocol violations, must be seronegative to the relevant HPV type at Day 1 and PCR negative to
the relevant HPV type Day 1 through Month 7, and must provide follow-up data after Month 7.</population>
          <units>Detection per 100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1390"/>
                <count group_id="O2" value="1402"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Relative Risk Reduction</param_type>
            <param_value>51.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>40.3</ci_lower_limit>
            <ci_upper_limit>59.9</ci_upper_limit>
            <estimate_desc>CI based on binomial tail probabilities and not from a dispersion parameter. Hochberg multiplicity adjustment applied to the CI.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Substudy to Evaluate the Incidence of HPV 6/11/16/18-related Anal Intraepithelial Neoplasia (AIN) and Anal Cancer in Men Having Sex With Men (MSM)</title>
        <description>Participants with HPV 6/11/16/18-related AIN or anal cancer per 100 person-years of follow-up</description>
        <time_frame>Base study: through Month 36</time_frame>
        <population>Only a subset of the enrolled population was used for the analysis of this substudy. Per-protocol participants that were naïve to the relevant vaccine HPV types at enrollment and remained PCR negative to the relevant types through the vaccination period, including the Month 7 visit were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time participants received qHPV vaccination at Day 1, Month 2 and Month 6.
Follow-up for the base study encompassed Month 7 through Month 36. Not all participants reached Month 36 prior to the cut-off for the pre-specified analysis.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time participants received placebo at Day 1, Month 2 and Month 6.
Follow-up for the base study encompassed Month 7 through Month 36. Not all participants reached Month 36 prior to the cut-off for the pre-specified analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Substudy to Evaluate the Incidence of HPV 6/11/16/18-related Anal Intraepithelial Neoplasia (AIN) and Anal Cancer in Men Having Sex With Men (MSM)</title>
          <description>Participants with HPV 6/11/16/18-related AIN or anal cancer per 100 person-years of follow-up</description>
          <population>Only a subset of the enrolled population was used for the analysis of this substudy. Per-protocol participants that were naïve to the relevant vaccine HPV types at enrollment and remained PCR negative to the relevant types through the vaccination period, including the Month 7 visit were analyzed.</population>
          <units>Incidence per 100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Relative Risk Reduction</param_type>
            <param_value>77.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>39.6</ci_lower_limit>
            <ci_upper_limit>93.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Severe Injection Site Adverse Experiences (AEs)</title>
        <time_frame>Base study: through Day 5 after any vaccination</time_frame>
        <population>All participants receiving at least 1 vaccination with qHPV vaccine or placebo in the base study</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time participants received qHPV vaccination at Day 1, Month 2 and Month 6.
Follow-up for the base study encompassed Month 7 through Month 36. Not all participants reached Month 36 prior to the cut-off for the pre-specified analysis.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time participants received placebo at Day 1, Month 2 and Month 6.
Follow-up for the base study encompassed Month 7 through Month 36. Not all participants reached Month 36 prior to the cut-off for the pre-specified analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Severe Injection Site Adverse Experiences (AEs)</title>
          <population>All participants receiving at least 1 vaccination with qHPV vaccine or placebo in the base study</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2020"/>
                <count group_id="O2" value="2029"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Vaccine-Related Serious Adverse Events (SAEs)</title>
        <time_frame>Base study: through Month 36</time_frame>
        <population>All participants receiving at least 1 vaccination with qHPV vaccine or placebo in the base study</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine: Base Study and Followup</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time participants received qHPV vaccination at Day 1, Month 2 and Month 6.
Follow-up for the base study encompassed Month 7 through Month 36. The at-risk population was participants who received ≥ 1 qHPV vaccination in the base study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo: Base Study and Followup</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time participants received placebo at Day 1, Month 2 and Month 6.
Follow-up for the base study encompassed Month 7 through Month 36. The at-risk population was participants who received ≥ 1 placebo injection in the base study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vaccine-Related Serious Adverse Events (SAEs)</title>
          <population>All participants receiving at least 1 vaccination with qHPV vaccine or placebo in the base study</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2020"/>
                <count group_id="O2" value="2029"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Base study: all AEs were collected systematically from Day 1 through Month 36. Extension 1: SAEs were collected systematically from Day 1 through Month 7. Other AEs were not solicited during EXT1.</time_frame>
      <desc>Medical Dictionary for Regulatory Activities (MedDRA) version 12.0 was used during the base study and follow-up, and MedDRA version 14.1 was used during EXT1.
Although non-serious AEs were not solicited during EXT1, 1 participant voluntarily reported the non-serious AE of viral gastroenteritis (incidence &lt;1%).</desc>
      <group_list>
        <group group_id="E1">
          <title>qHPV Vaccine: Base Study</title>
          <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time participants received qHPV vaccination at Day 1, Month 2 and Month 6.
Follow-up for the base study encompassed Month 7 through Month 36. The at-risk population was participants who received ≥ 1 qHPV vaccination in the base study.</description>
        </group>
        <group group_id="E2">
          <title>Placebo: Base Study</title>
          <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time participants received placebo at Day 1, Month 2 and Month 6.
Follow-up for the base study encompassed Month 7 through Month 36. The at-risk population was participants who received ≥ 1 placebo injection in the base study.</description>
        </group>
        <group group_id="E3">
          <title>qHPV Vaccine: EXT1</title>
          <description>Participants who received placebo and participants who received only 1 dose of qHPV vaccine in the base study were offered a complete 3-dose qHPV vaccine regimen (administered at EXT1 Day 1, Month 2 and Month 6). Participants who received only 2 doses of qHPV vaccine in the base study were offered a single additional dose of qHPV vaccine (administered at EXT1 Day 1). Participants were followed to EXT1 Month 7. The at-risk population was participants who received ≥ 1 qHPV vaccination in EXT1 and had follow-up data.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1084"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1084"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1084"/>
              </event>
              <event>
                <sub_title>Pericardial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1084"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1084"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1084"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1084"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1084"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1084"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1084"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1084"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1084"/>
              </event>
              <event>
                <sub_title>Chemical poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1084"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1084"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1084"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1084"/>
              </event>
              <event>
                <sub_title>Multiple drug overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1084"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1084"/>
              </event>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1084"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1084"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1084"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1084"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1278" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="1185" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="125" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" subjects_affected="304" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="275" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="1113" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="991" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection Site Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling</sub_title>
                <counts group_id="E1" subjects_affected="219" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="187" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="179" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="207" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="2020"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="2029"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President, Late Stage Development Group Leader</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
